drugset / Trial / NCT00185692
Allogeneic Transplantation From Related Haploidentical Donors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the feasibility and safety of transplanting CD34+ selected hematopoietic cells from a haploidentical related donor following a nonmyeloablative regimen of total lymphoid irradiation (TLI) and antithymocyte globulin (ATG).
Timeline
- Start
- 2000-08
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | 1.5 mg/kg | Intravenous |
| Background | Acetaminophen | Small molecule | 650 mg | Oral |
| Background | Cyclosporine | Peptide | 6.25 mg/kg | Oral |
| Background | Diphenhydramine | Unknown | 50 mg | Intravenous |
| Background | G-CSF | Unknown | 16 mg/kg | Subcutaneous |
| Background | Hydrocortisone | Other / unclassified | 100 mg | Intravenous |
| Background | Methylprednisolone | Other / unclassified | 1 mg/kg | Intravenous |
| Background | Mycophenolate Mofetil | Small molecule | 15 mg/kg | Oral |